Latest From Biotech Now
Amid the cacophony of calls for patent reform legislation, mounting evidence demonstrates patent trolling may be on the wane. As we reported earlier this month, the number of new patent cases filed in federal court has dropped by an astonishing 40 percent as compared to this time last year. A new data analysis by Unified Patents data shows more signs that patent troll suits are in decline.
Lung cancer is the leading cause of cancer death in the US, taking the lives of twice as many women as breast cancer and three times as many men as prostate cancer. While a history of smoking is the main risk factor for developing lung cancer, nearly 80% of those diagnosed today were never smokers or are former smokers who quit decades ago. November is Lung Cancer Awareness Month, a time of reflection for advocates Read More >
Earlier this week, John Fauber of the Milwaukee Journal Sentinel wrote an article on measures used to determine whether new medicines for serious and life-threatening diseases should reach patients. Fauber seem(s) to suggest that the use of surrogate measures – such as tumor shrinkage – do not provide evidence of drug efficacy. The story fails to present a balanced view of the complex benefit-risk assessments that the FDA must carefully consider when reviewing applications for Read More >
The Washington Post recently published a piece titled The GMO Debate: 5 Things to Stop Arguing, which looks at common arguments surrounding the use of genetically modified organism (GMOs) and how they have lost their vigor. Specifically in her article, Tamar Haspel suggests 5 somethings taken from both sides of the debate that need to be retired. Haspel argues that moving beyond these 5 points could mean moving one step forward in achieving a happy medium between the two parties. 1. GMOs are Read More >
On November 4th, citizens in Colorado and Oregon will have to decide on whether or not to approve contentious ballot initiatives that would require the mandatory labeling of certain products containing genetically modified organisms (GMOs). The editorial board of the Wall Street Journal wrote an interesting piece that takes a look at what the organic industry will gain if these labeling initiatives pass. It turns out quite a lot: “If you can’t beat them, ask Read More >